Fri, 18 Jun 2021 09:15:48: FDA rejects Orphazyme's rare disease drug, continuing wild ride for Danish meme stock

Fri, 18 Jun 2021 08:21:36: Bristol Myers pays $650M for rights to Eisai's phase 1 ADC

Thu, 17 Jun 2021 20:22:32: Chutes & Ladders—Ex-FDA chief Hahn joins Moderna backer

Thu, 17 Jun 2021 14:20:09: Targeting treatment-resistant BRCA-mutated tumors via the newly discovered POLQ pathway

Thu, 17 Jun 2021 11:40:29: Targeting 'enabler cells' to stop the spread of triple-negative breast cancer

Thu, 17 Jun 2021 10:01:39: Lilly helps Circle round up $66M for intractable target R&D

Thu, 17 Jun 2021 09:15:19: Biogen's $300M bet on Alzheimer's tau drug snapped up from Bristol Myers flames out in phase 2

Wed, 16 Jun 2021 21:09:35: CureVac's first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading

Wed, 16 Jun 2021 12:29:55: New COVID-19 approach exploits protein response in human cells to combat virus

Wed, 16 Jun 2021 12:13:06: Molecular Partners prices $64M IPO, falling short of original goal

Wed, 16 Jun 2021 10:10:22: Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect

Tue, 15 Jun 2021 16:49:07: Evotec wants to prevent the next COVID-19 crisis, and you could help

Tue, 15 Jun 2021 09:53:38: VectorY raises $38M to develop Alzheimer's, ALS gene therapies

Tue, 15 Jun 2021 09:13:59: AstraZeneca's COVID-19 antibody combination fails post-exposure prevention trial

Mon, 14 Jun 2021 15:20:26: Diabetes mainstay metformin tamps down lung inflammation in COVID models

Mon, 14 Jun 2021 09:39:02: EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice

Mon, 14 Jun 2021 08:56:29: GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race

Mon, 14 Jun 2021 07:50:59: Novavax COVID-19 vaccine hits 90% efficacy in pivotal U.S. trial

Fri, 11 Jun 2021 10:37:19: Sanofi's treatment for rare anemia hits goal in 2nd phase 3

Fri, 11 Jun 2021 08:52:37: Harvard's Kesselheim quits AdComm over FDA's Aduhelm approval

Fri, 11 Jun 2021 08:24:51: Eli Lilly, Roche's Alzheimer's prospects, including flops, boosted in light of FDA's Aduhelm approval: analysts

Thu, 10 Jun 2021 19:02:17: Chutes & Ladders—FDA nod for Biogen's Aduhelm sees trio of AdComm members hit the exit

Thu, 10 Jun 2021 13:18:58: Acumen rides aducanumab, amyloid and Alzheimer's waves on its IPO voyage

Thu, 10 Jun 2021 12:05:11: Kurome raises $15M to overcome adaptive resistance in leukemia

Thu, 10 Jun 2021 09:55:28: AdComm exodus: 2nd expert quits over FDA approval of Biogen's Aduhelm